Fukudo S, et al. - Researchers performed a randomized, double-blind, placebo-controlled (Part 1) and long-term, open-label extension (Part 2) study of linaclotide at 60 hospitals and clinics in Japan to test the impact of linaclotide 0.5 mg/d in patients with irritable bowel syndrome with constipation (IBS-C). The findings from the present study suggested that a linaclotide dose of 0.5 mg was effective and safe for IBS-C patients in Japan.